Would you consider adjuvant capecitabine for a patient with triple-negative metaplastic carcinoma who has microinvasive residual disease (ypT1miN0) following neoadjuvant therapy?
Does the metaplastic histology influence your decision-making?
Community PollStarted
Do you off adjuvant capecitabine to patients with triple-negative metaplastic breast cancer with ypT1miN0 following neoadjuvant therapy?
50 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Huntsman Cancer Institute at the University of Utah
Answered on
For a patient with triple-negative metaplastic breast cancer and microinvasive residual disease (ypT1miN0)following neoadjuvant therapy, the decision to use adjuvant capecitabine is nuanced and not definitively addressed in current guidelines or trials.
- General TNBC with Residual Disease:
- Multiple...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Baylor College of Medicine
Answered on
Short answer: yes. Although we have data from CREATE-X, data from GEICAM were negative. Data from FinXX and SYSUCC001, however, were positive. TNBC still carries a high risk of recurrence even with small-volume residual disease. Retrospective and prospective data suggest that chemotherapy is particu...
Join for free or sign in to see the full answer